· Published by Health Canada · Official notice
This is duplicated text of a letter from Janssen Inc. Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
November 18, 2014
Subject: New safety information regarding the risk of serious skin reactions associated with the use of REMINYL® ER (galantamine hydrobromide)
Janssen Inc., in consultation with Health Canada, is informing consumers about important new safety information regarding the risk of serious skin reactions associated with the use of REMINYL® ER. This safety information also applies to generic versions of galantamine.
REMINYL® ER is used to treat the symptoms of mild to moderate Alzheimer’s disease (a type of dementia), a disease that alters brain function.
Signs of skin reactions may include:
Janssen Inc. has provided this information to doctors, pharmacists, and long-term care facilities across Canada. For more information, patients should consult their health care professional. The CONSUMER INFORMATION document is available at the Janssen Canada Web site.
Managing marketed health product-related side effects depends on healthcare professionals and consumers reporting them. Cases of skin or other serious or unexpected adverse reactions in patients receiving REMINYL® ER should be reported to Janssen Inc. or Health Canada.
Drug Safety Department
Janssen Inc.
19 Green Belt Drive
Toronto, Ontario
M3C 1L9
Or call toll free at 1-866-825-7122
Or email to dsscan@joica.jnj.com
Or fax to 1-866-767-5865
You can report any suspected side effect associated with the use of health products to Health Canada by:
For other health product inquiries related to this communication, contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc.public@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
original signed by
Cathy Lau, Ph.D.
Vice President
Regulatory Affairs and Quality Management